Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
7
Neutral
1
Bullish
6
Bearish
7
Neutral
1
Bullish
38
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Transchem Limited initially engaged in chemicals and pharmaceuticals, transitioned toward mushroom production, operating a 100% Export Oriented Unit in Pune. However, this plant became non-operational due to changes in the horticulture industry.
The company manufactures bulk drugs primarily in Maharashtra, with frusemide, fenbendazole, and albendazole as key products.
Transchem has signed a Memorandum of Understanding with a Dutch company for its mushroom project, previously entering into agreements for technical collaborations.
Previously, Transchem was recognized for its mushroom cultivation and international sales of various compounds, including Diminazine Aceturate and Triclabendazole.
In 2008, the company exited the pharmaceutical division, indicating a strategic shift away from that sector.
Pharmaceuticals & Biotechnology
Pharmaceuticals
350 Cr
Low Risk
81.6
33.9
3.7
4.2
300.15
37.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
73.00 | 401 Cr | -122.25 | 1.29 | 0.00 | -1.05 | 0.74 | -0.71 | ||
229.65 | 394 Cr | 85.25 | 19.71 | 0.00 | 19.79 | 23.50 | 10.61 | ||
45.85 | 382 Cr | 29.11 | 5.06 | 0.00 | 17.38 | 20.98 | 8.55 | ||
285.90 | 350 Cr | 81.57 | 4.19 | 0.00 | 5.14 | 6.71 | 4.89 | ||
242.50 | 333 Cr | 30.61 | 1.21 | 0.41 | 3.50 | 4.79 | 2.63 | ||
207.50 | 323 Cr | 26.61 | 2.67 | 0.00 | 10.04 | 16.02 | 8.12 | ||
72.77 | 315 Cr | 33.79 | 0.93 | 0.00 | 4.41 | 5.15 | — | ||
| Median: 7 Co. | — | 207.50 | 350 Cr | 30.61 | 2.67 | 0.00 | 5.14 | 6.71 | 6.50 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Transchem Ltd (TRANSCHEM) is currently trading at 290.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Transchem Limited initially engaged in chemicals and pharmaceuticals, transitioned toward mushroom production, operating a 100% Export Oriented Unit in Pune. However, this plant became non-operational due to changes in the horticulture industry. The company manufactures bulk drugs primarily in Maharashtra, with frusemide, fenbendazole, and albendazole as key products. Transchem has signed a Memorandum of Understanding with a Dutch company for its mushroom project, previously entering into agreements for technical collaborations. Previously, Transchem was recognized for its mushroom cultivation and international sales of various compounds, including Diminazine Aceturate and Triclabendazole. In 2008, the company exited the pharmaceutical division, indicating a strategic shift away from that sector.
Over the past 52 weeks, Transchem Ltd has traded between a low of ₹37.00 and a high of ₹300.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Transchem Ltd has a market capitalization of approximately 349.94. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Transchem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 81.57 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 349.94 Cr, Transchem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Transchem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Transchem Ltd is 81.57. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Warrant Acquisition
Bakkt Opco Holdings, LLC disclosed acquisition of 47,500,000 warrants in Transchem Limited on June 3, 2026, representing 64.42% of Transchem's total diluted share/voting capital; prior holding nil; acquirer is not a promoter.
Substantial acquisition
On 3 June 2026, Bakkt Opco Holdings, LLC disclosed acquisition of 47,500,000 warrants in Transchem Limited (BSE:500422), representing ~64.42% of Transchem's diluted share/voting capital; prior holding was nil.
Warrant allotment
On June 3, 2026 Pishu V. Chainani was allotted 1,20,00,000 warrants of Transchem Limited via preferential allotment; each warrant convertible into one equity share within 18 months, representing 19.51% of diluted capital; acquirer is not a promoter.
Warrant Allotment
On June 3, 2026 Pishu V. Chainani was allotted 12,000,000 warrants of Transchem Limited by preferential allotment, each convertible into one equity share within 18 months, representing ~19.51% of diluted share capital.
Preferential Warrant Allotment
Transchem Ltd allotted 6.15 crore warrants at Rs.75 each on a preferential basis (25% upfront received totaling Rs.115.31 Cr) to four non‑promoter allottees; warrants convertible to equity within 18 months, potential raise Rs.461.25 Cr.
Preferential allotment
Transchem’s Preferential Issue Committee on June 3, 2026 approved allotment of 6,15,00,000 warrants at Rs.75 each (25% upfront paid) to four non‑promoter allottees; Rs.115.31 crore received upfront; warrants convertible to equity within 18 months.
